Clinical Trial Update: An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluated daratumumab in relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: TERMINATED | Results posted: 2018-06-26